Identification of a six-lncRNA signature associated with recurrence of ovarian cancer.

Related Articles

Identification of a six-lncRNA signature associated with recurrence of ovarian cancer.

Sci Rep. 2017 Apr 07;7(1):752

Authors: Yang K, Hou Y, Li A, Li Z, Wang W, Xie H, Rong Z, Lou G, Li K

Abstract
Ovarian cancer (OvCa) is the leading cause of death among all gynecological malignancies, and recurrent OvCa is almost always incurable. In this study, we developed a signature based on long non-coding RNAs (lncRNAs) associated with OvCa recurrence to facilitate personalized OvCa therapy. lncRNA expression data were extracted from GSE9891 and GSE30161. LASSO (least absolute shrinkage and selection operator) penalized regression was used to identify an lncRNA-based signature using the GSE9891 training cohort. The signature was then validated in GSE9891 internal and GSE30161 external validation cohorts. The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to explore the possible functions of identified lncRNAs. A six-lncRNA signature (RUNX1-IT1, MALAT1, H19, HOTAIRM1, LOC100190986 and AL132709.8) was identified in the training cohort and validated in internal and external validation cohorts using the LASSO method (P < 0.05). This signature was also independent of other clinical factors according to multivariate and sub-group analyses. The identified lncRNAs are involved in cancer-related biological processes and pathways. We selected a highly reliable signature based on six lncRNAs associated with OvCa recurrence. This six-lncRNA signature is a promising method to personalize ovarian cancer therapy and may improve patient quality of life quality according to patients' condition in the future.

PMID: 28389671 [PubMed - in process]

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2oS0VHt
via IFTTT